Skip to main content
Download PDF

The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study

BMC Psychiatry volume 24, Article number: 399 (2024) Cite this article

Abstract

Background

To examine whether the "Effectiveness of Guideline for Dissemination and Education in psychiatric treatment (EGIUDE)" project affects the rate of prescriptions of hypnotic medication and the type of hypnotic medications prescribed among psychiatrists, for schizophrenia and major depressive disorder in Japan.

Methods

The EGUIDE project is a nationwide prospective study of evidence-based clinical guidelines for schizophrenia and major depressive disorder in Japan. From 2016 to 2021, clinical and prescribing data from patients discharged from hospitals participating in the EGUIDE project were used to examine hypnotic medication prescriptions The prescribing rate of hypnotics and the prescribing rate of each type of hypnotic (benzodiazepine receptor agonist, nonbenzodiazepine receptor agonist, melatonin receptor agonist, and orexin receptor antagonist) were compared among patients who had been prescribed medication by psychiatrists participating in the EGUIDE project and patients who had been prescribed medication by nonparticipating psychiatrists. Multivariate logistic regression analysis was performed to examine the effect of the EGUIDE project on the prescription of hypnotic medications.

Results

A total of 12,161 patients with schizophrenia and 6,167 patients with major depressive disorder were included. Psychiatrists participating in the EGUIDE project significantly reduced the rate of prescribing hypnotic medication and benzodiazepine receptor agonists for both schizophrenia (P < 0.001) and major depressive disorder (P < 0.001) patients.

Conclusion

This is the first study to investigate the educational effects of guidelines for the treatment of psychiatric disorders on psychiatrists in terms of prescribing hypnotic medications to patients. The EGUIDE project may play an important role in reducing hypnotic medication prescription rates, particularly with respect to benzodiazepine receptor agonists. The results suggest that the EGUIDE project may result in improved therapeutic behavior.

Peer Review reports

Background

Evidence-based medicine (EBM) involves the integration of research evidence and clinical expertise with patient intentions, behaviors, clinical situations, and environments to facilitate better decisions for patient care [1]. In clinical practice, clinical guidelines based on EBM have been developed and used to support professional-patient decision-making [2]. Meta-analyses have shown that patients with psychiatric disorders who are treated in accordance with guidelines show greater and faster recovery than patients treated with standard therapies [3]. On the other hand, it has been noted that in clinical practice, it is not uncommon for medical practices to fall outside the guidelines, and numerous medical practices diverge from established guidelines due to insufficient awareness, unfamiliarity, and disagreement with these guidelines [4].

In Japan, to implement disease treatment guidelines in clinical psychiatric practice, the Effectiveness of Guideline for Dissemination and Education in Psychiatric Treatment (EGIUDE) project was designed to educate psychiatrists about the pharmacological therapy of schizophrenia [5] and the treatment guidelines for major depressive disorder [6]. Furthermore, the EGUIDE project aimed to examine the effectiveness of guideline education by conducting follow-up studies of changes in knowledge and prescribing behavior [7]. Previous studies have shown that participation in the EGUIDE project improves participants' knowledge of and attitudes toward adhering to guidelines [7, 8] and that these effects are maintained for at least two years [9]. Moreover, participation in the EGUIDE project has been shown to be effective in improving psychiatrists' treatment-related behaviors, including antipsychotic monotherapy for schizophrenia patients and antidepressant monotherapy for major depressive disorder patients [10].

The evidence in the clinical setting regarding the use of hypnotic medication in the treatment of schizophrenia and major depressive disorder is still not clear. Although insomnia has been reported in up to 80% of patients with schizophrenia [11] and more than 90% of patients with major depressive disorders [12], in some cases as a cause and in others as a consequence [13], clinical evidence for the efficacy of hypnotic medication treatment for insomnia in patients with psychiatric disorders is limited. In this context, clinical guidelines that recommend against long-term use of prescription hypnotic medication for insomnia among patients with schizophrenia or major depressive disorder have been established [14, 15] including in Japan [5, 6]. Therefore, the EGUIDE project analyzed a large dataset of prescriptions for schizophrenia and major depressive disorder inpatients treated by physicians who had not attended a guideline course and found a high rate of prescription of hypnotic medication (55.7% of schizophrenia inpatients and 63.6% of major depressive disorder inpatients), thus revealing a potential evidence-practice gap [16].

In examining the effectiveness of EGUIDE training for prescribing hypnotic medications, it was necessary to consider the following two points in light of the current state of medical care in Japan. First, the types of hypnotic medications used in clinical practice have changed over time. Recently, orexin receptor antagonists (ORA), which are novel hypnotic medications with novel mechanisms of action, have been developed, and studies using large Japanese databases have shown that the types of hypnotic medications used have changed significantly [17, 18]. The second is the recent reform of the reimbursement system for prescribing hypnotic medications. In Japan, medical reimbursement was revised from 2012 to 2018 to optimize the prescription of hypnotic medications, and reimbursement was reduced for prescribing 3 or more sleeping pills per patient simultaneously [19].

In the present study, we used a cross-sectional survey to analyze prescription rates obtained from a database of inpatients with schizophrenia and major depressive disorder. We aimed to determine whether there is a difference in the prescribing rates of hypnotic medications between patients treated by psychiatrists who participated in the EGUIDE project and patients treated by nonparticipating psychiatrists. The objectives of this study were to determine 1) whether there is a difference in the rate of prescribing hypnotic medications between patients treated by psychiatrists who participated in the EGUIDE project and patients treated by nonparticipating psychiatrists and 2) whether there is a difference in the types of hypnotic medications prescribed for patients treated by psychiatrists who participated in the EGUIDE project and patients treated by nonparticipating psychiatrists.

Methods

Study design

The study is a multicenter, historical starting point cohort study; 267 medical facilities in Japan participated in the EGUIDE project between 2016 and 2021. Psychiatrists affiliated with participating facilities could self-select to participate in the EGUIDE project intervention. When psychiatrists participated in the EGUIDE project, they attended one lecture on each of the guidelines for schizophrenia and major depressive disorder. Patient data were collected from patients with schizophrenia and major depressive disorder at participating hospitals. These patient data were divided into two groups: patients treated by psychiatrists participating in the EGUIDE project (EGUIDE ( +)) and patients treated by psychiatrists not participating in the EGUIDE project (EGUIDE (-)), as described in a previous study. If both EGUIDE ( +) and EGUIDE (-) patients were assigned to the same patient, they were assigned to the EGUIDE ( +) group [10].

The EGUIDE project consisted of two days of training: one day of training on drug treatment for schizophrenia and one day of training on treatment for depression. The lecture on sleep lasted 15 to 20 min and included the identification of sleep disorders, guidance on sleep hygiene, cognitive‒behavioral therapy approach to insomnia, and points to keep in mind during drug therapy. Both disease courses lack of evidence for long-term prescribing of benzodiazepines and the risk of side effects with long-term use. The diagnosis and treatment of sleep disorders were also discussed in small-group case studies.

Objectives

The primary outcome of the study were the rate of prescriptions of hypnotic medications among inpatients with schizophrenia and major depressive disorder and the rate of prescriptions of hypnotic medications by type of hypnotic medication.

Participants

Psychiatrists

A total of 1021 psychiatrists from 267 medical facilities (48 university hospitals, 79 public hospitals, and 140 private hospitals) participating in the EGUIDE project between 2016 and 2021 attended one guideline course each on schizophrenia and major depressive disorder. Participation in the EGUIDE project was voluntary for psychiatrists from EGUIDE-participating institutions.

Patients

Treatment data were collected from patients with schizophrenia and patients with major depressive disorder who were discharged from the participating facilities [7, 10, 16]. Patients who were hospitalized for less than 3 days or hospitalized for laboratory purposes only were excluded. Patients were diagnosed according to DSM-5 diagnostic criteria [20], with no overlap between schizophrenia and major depressive disorder. However, the comorbidity of other diagnoses, such as substance use disorders, was not assessed.

Data collected

The following patient information was collected: age, gender, type of facility, whether modified electroconvulsive therapy (mECT) was administered, and whether the attending physician participated in the EGUIDE project. Data regarding the prescription of hypnotic medications, antipsychotics, anticholinergics, antidepressants, anxiolytics, and mood stabilizers/antiepileptics were collected at discharge. In addition to whether hypnotic medication was prescribed, we also identified whether benzodiazepine receptor agonists (BZA), which are classified as hypnotic medications, nonbenzodiazepine receptor agonists (nBZA), melatonin receptor agonists (MRA), or ORA, were prescribed. The classification of hypnotic medication type was determined based on previous studies [16, 21]. We investigated whether schizophrenia patients were prescribed no antipsychotics, one antipsychotic or two or more antipsychotics and whether major depressive disorder patients were prescribed no antidepressants, one antidepressant or two or more antidepressants. We assessed whether electroconvulsive therapy was administered during hospitalization.

Statistical analysis

Chi-square tests were used to compare categorical variables, and independent samples t tests were used to compare continuous variables between the EGUIDE ( +) and EGUIDE (-) groups. Multivariate logistic regression analysis was performed to examine the effect of the EGUIDE project on the use of hypnotic medications. The objective variables were the presence or absence of prescriptions for hypnotic medication, BZA, nBZA, MRA, and ORA. First, univariate analysis was conducted to examine factors associated with whether the patient was treated by a psychiatrist who participated in the EGUIDE project. Next, we adjusted for patient age, gender, and treatment facility (adjusted a). Then, we adjusted for electroconvulsive therapy, antipsychotics, anticholinergics, antidepressants, anxiolytics, and mood stabilizers/antiepileptics (adjusted b). Finally, we adjusted for the year of discharge (adjusted c). Ten tests (schizophrenia, major depressive disorder, sleeping pills, BZA, nBZA, MRA, and ORA) were performed to examine the effect of participation in the EGUIDE project, so Bonferroni correction was used, and the statistical significance level was set at P < 0.005 (0.05/10). Statistical analyses were performed using SPSS version 29 (IBM Corp., Armonk, NY).

Results

The demographic characteristics of the EGUIDE + psychiatrists were as follows: percentage of men, 71.5%; mean age (standard deviation), 32.8 (7.0) years; and mean years of psychiatric experience at the beginning of the course, 3.9 (5.8) years. Between 2016 and 2021, a total of 14,187 patients with schizophrenia and 6,990 patients with major depressive disorder were discharged. We excluded patients with incomplete prescription information, mistyped prescription information, extremely high doses (chlorpromazine equivalent ≥ 2,000 mg/day, imipramine equivalent ≥ 350 mg/day, biperiden equivalent ≥ 7 mg/day, or diazepam equivalent ≥ 25 mg/day) (n = 85 for schizophrenia, n = 142 for major depressive disorder) or rehospitalization during the study period (n = 1,941 for schizophrenia and n = 681 for major depressive disorder). Ultimately, 12,161 patients with schizophrenia and 6,167 patients with major depressive disorder were included (Fig. 1).

Fig. 1
figure 1

Flowchart of patient inclusion

Full size image

Among patients with schizophrenia, in the EGUIDE ( +) and EGUIDE (-) groups, respectively, the percentage of males was 43.0% and 45.6%, and the mean age (standard deviation) was 46.08 (15.20) and 46.53 (15.83) (Table 1), and among patients with major depressive disorder, the percentage of males was 34.6% and 34.1%, and the mean age (standard deviation) was 58.14 (18.44) and 57.70 (18.38) (Table 2). The prescription rates of hypnotic medication in the EGUIDE ( +) and EGUIDE (-) groups were 50.9% and 57.5% (P < 0.001), respectively, for schizophrenia patients and 60.3% and 66.3% (P < 0.001), respectively, for major depressive disorder patients. Among patients with schizophrenia, in the EGUIDE ( +) and EGUIDE (-) groups, the respective prescription rates of BZA were 32.5% and 40.9% (P < 0.001), those of nBZA were 9.0% and 10.9% (P = 0.001), those of MRA were 4.0% and 4.1% (P = 0.827), those of ORA were 18.2% and 15.5% (P < 0.001). Among patients with major depressive disorder, the respective prescription rates of BZA were 26.1% and 35.6% (P < 0.001), those of nBZA were 16.4% and 18.5% (P = 0.034), those of MRA were 7.6% and 6.9% (P = 0.225), and those of ORA were 28.3% and 25.4% (P = 0.012). To determine whether participation in the EGUIDE project had any effect on the choice of hypnotic medication, multivariable logistic regression analysis was used to examine the effect of participation in the EGUIDE project. Multivariate logistic regression analysis to determine whether participation in the EGUIDE project had any effect on the choice of hypnotic medication revealed that EGUIDE ( +) significantly reduced the rate of prescribing hypnotic medication in both patients with schizophrenia (OR, 0.799; 95% CI, 0.736–0.866; P < 0.001) (Table 3) and patients with major depressive disorder (OR, 0.816; 95% CI, 0.728–0.915; P < 0.001) (Table 4) in all the models, adjusted or not. Next, when examined by type of hypnotic medication, the proportion of BZA prescriptions was significantly lower in schizophrenia patients (OR, 0.793; 95% CI, 0.729–0.863; P < 0.001) (Table 3) and those with major depressive disorder (OR, 0.771; 95% CI, 0.682–0.871; P < 0.001) (Table 4) in all models, adjusted or not. The proportion of nBZA prescriptions was significantly lower in schizophrenia patients in unadjusted, adjusted a, and adjusted b, and the proportion of ORA prescriptions was significantly higher in schizophrenia in patients unadjusted, adjusted a, and adjusted b (Table 3).

Table 1 Characteristics of the patients with schizophrenia
Full size table
Table 2 Characteristics of the patients with major depressive disorder
Full size table
Table 3 Logistic regression analysis showing the adjusted effects (odds ratios with 95% CIs) between the EGUIDE project and hypnotic medication use in patients with schizophrenia (n = 12,161)
Full size table
Table 4 Logistic regression analysis showing the adjusted effects (odds ratios with 95% CIs) between the EGUIDE project and hypnotic medication use in patients with major depressive disorder (n = 6,167)
Full size table

Discussion

This is the first study to investigate the educational effects of guidelines for the treatment of psychiatric disorders in terms of prescribing hypnotic medications for patients with schizophrenia and major depressive disorder on psychiatrists in Japan.

The results of this study revealed that psychiatrists who attended the EGUIDE project prescribed hypnotic medication at significantly lower rates, including significantly lower rates of prescribing BZA. Few studies have investigated the actual prescription rate of hypnotic medications in the treatment of psychiatric disorders. In clinical studies examining patients with schizophrenia, hypnotic medications were prescribed in 11.2% to 55.7% of patients [16, 22], and in studies of major depressive disorder patients, they were prescribed in 29.6% to 63.6% of patients [16, 23]. Although insomnia is often a persistent condition [24] and several novel mechanisms of action of hypnotic medications have recently been shown to be effective and safe for long-term use in appropriate clinical settings [25], long-term pharmacotherapy with BZA, which is often used in real-world clinical practice, is associated with falls, delirium, cognitive decline, respiratory depression, dependence and withdrawal [26], as well as the risk of being used in suicide attempts [27].

There are several possible methods to optimize the prescription of hypnotic medications. First, postgraduate education for psychiatrists working at the front line of treatment on basic medical treatment methods and treatment techniques for psychiatric patients with sleep problems is considered an important option to promote behavioral change among psychiatrists. It has been previously reported that participation in the EGUIDE project increased psychiatrists' expertise and changed their practice behavior [7, 9, 10]. The second method is to provide more specialized sleep treatment. Cognitive behavioral therapy for insomnia (CBT-I) is considered an important therapeutic option for chronic insomnia, and there is some evidence that it leads to a reduction in the use of hypnotic medications [28]. However, in Japan, as in other Western countries, access to CBT-I is limited, and it is not commonly provided in primary care [29]. The third method is to revise medical fees. In Japan, reimbursement was revised three times between 2012 and 2018 to promote the appropriate use of hypnotic medications, reducing reimbursement for prescribing three or more hypnotic medications in a single prescription [19]. This revision was shown to reduce the rate of polypharmacy, but the effect on long-term prescriptions is not clear [30].The introduction of secure prescription pads in France serves as another example of regulatory intervention. This initiative notably reduced zolpidem exposure among chronic users, extensively altered prescribing behaviors for other sedatives, and increased general practitioners’ understanding of hypnotic medication risks [31, 32]. Since the present study lacked clinical information on the importance of patients' psychiatric symptoms and insomnia symptoms, it is not possible to judge whether the treatment is appropriate or not only because of the lower rate of prescription of hypnotic medication. However, because long-term prescribing of hypnotic medication is not recommended in treatment guidelines in Japan [5, 6] or Western countries [14, 15] and because administrative-level measures against prescribing of hypnotic medication are needed in the Japanese medical field [30], the prescribing behavior of physicians who participate in education programs should be more appropriate, thereby improving the evidence-practice gap.

The current survey showed that BZA prescriptions are less common among psychiatrists who participate in the EGUIDE project. There are two possible interpretations for this. The first is a possible effect of EGUIDE training. Although the EGUIDE training does not recommend prescribing a specific type of hypnotic medication, as the treatment guidelines in Japan [5, 6] do not change the recommendation according to the type of hypnotic medication, it does alert participants to the side effects of BZA in general and to the fact that long-term, indolent treatment may not be useful in the treatment of patients. EGUIDE training also increased clinical behavior in accordance with treatment guidelines, which were maintained two years later [9]. Therefore, prescribing behavior may be changing among EGUIDE ( +) psychiatrists toward avoiding prescribing BZA more as a hypnotic medication. Second, it may reflect changes in the prescription of hypnotic medications over time. A study using the Japanese clime database reported a significant decrease in BZA and an increase in ORA from 2010 to 2019 [17]. However, this study took this into account and adjusted for the year in which the data were obtained as a covariate. While ORA lost significance at adjusted c and was affected by the year, BZA had significant differences at adjusted c as well. Therefore, it is unlikely that group differences were observed solely due to changes over time. Therefore, it is difficult to assume that differences between groups were found only by changes over time.

The current study has several limitations. First, this study did not use random assignment regarding participation in the EGUIDE project. Therefore, participants in the EGUIDE project included many who were highly motivated to practice EBM and EGUIDE ( +) psychiatrists and EGUIDE (-) psychiatrists may not treat the same type of patient. These factors may have led to selection bias. It is known that EGUIDE (-) practitioners are investigated for prescribing patterns, as EGUIDE facilities investigate prescribing patterns. However, EGUIDE ( +) may have led to a reduction in the prescription rate of hypnotic medications, as it is clearly explained at the time of attending EGUIDE that prescribing patterns would be investigated. Second, the study was cross-sectional with prescribing patterns assessed at one point in time. It was impossible to assess whether guideline education affects the long-term prescription of hypnotic medications. Third, there was no information on gender, age, or years of psychiatric experience in the EGUIDE(-) group, and information was shared between those who took the course and those who did not take the course within the same facility, which may have contaminated the effectiveness of the intervention. In the future, it may be necessary to collect data from facilities that do not participate in the EGUIDE project to make comparisons between facilities. Fourth, clinical data on symptoms and disease severity of treated patients were not assessed using rating scales. Future studies should use clinical symptom measurement scales, including observer-rated or self-rated scales, such as the Positive and Negative Syndrome Scale, the Beck Depression Inventory, or the RU-SATED, a self- rated sleep scale for the measurement of multidimensional sleep health　[33, 34]. Fifth, other confounding factors, such as length of hospitalization and number of patients with substance use disorders, that were not adjusted for in the present study may have influenced the results.

Conclusions

This study investigated the effects of educating psychiatrists on disease treatment guidelines based on the actual prescribing of hypnotic medication for the patients they treated and found that psychiatrists who participated in the EGUIDE project had a significantly lower rate of prescribing hypnotic medication and a significantly lower rate of BZA prescriptions according to the type of hypnotic medication. The results suggest that educational activities involving evidence-based treatment guidelines may play an important role in the postgraduate education of psychiatrists to optimize therapeutic behavior.

Availability of data and materials

The datasets analyzed during the current study are not publicly available due to informed consent, which has not been obtained for the release of raw data but is available from the corresponding author upon reasonable request.

Abbreviations

BZA:

Benzodiazepine receptor agonist

CBT-I:

Cognitive behavioral therapy for insomnia

EBM:

Evidence-based medicine

EGUIDE:

Effectiveness of Guideline for Dissemination and Education in psychiatric treatment

mECT:

Modified electroconvulsive therapy

MRA:

Melatonin receptor agonists

nBZA:

Nonbenzodiazepine receptor agonists

ORA:

Orexin receptor antagonists

References

  1. Haynes RB, Devereaux PJ, Guyatt GH. Physicians’ and patients’ choices in evidence based practice. BMJ. 2002;324(7350):1350. https://doi.org/10.1136/bmj.324.7350.1350.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Djulbegovic B, Guyatt GH. Progress in evidence-based medicine: a quarter century on. Lancet. 2017;390(10092):415–23. https://doi.org/10.1016/S0140-6736(16)31592-6.

    Article  PubMed  Google Scholar 

  3. Setkowski K, Boogert K, Hoogendoorn AW, Gilissen R, van Balkom A. Guidelines improve patient outcomes in specialised mental health care: A systematic review and meta-analysis. Acta Psychiatr Scand. 2021;144(3):246–58. https://doi.org/10.1111/acps.13332.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Barth JH, Misra S, Aakre KM, Langlois MR, Watine J, Twomey PJ, Oosterhuis WP. Why are clinical practice guidelines not followed? Clin Chem Lab Med. 2016;54(7):1133–9. https://doi.org/10.1515/cclm-2015-0871.

    Article  CAS  PubMed  Google Scholar 

  5. Japanese Society of Neuropsychopharmacology. Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia.” Neuropsychopharmacol Rep. 2021;41(3):266–324. https://doi.org/10.1002/npr2.12193.

    Article  PubMed Central  Google Scholar 

  6. Japanese Society of Mood Disorders. Japanese Society of Mood Disorders. Treatment Guideline II. 2nd ed. Tokyo: Igakusyoin; 2017.

    Google Scholar 

  7. Takaesu Y, Watanabe K, Numata S, Iwata M, Kudo N, Oishi S, Takizawa T, Nemoto K, Yasuda Y, Tagata H, et al. Improvement of psychiatrists’ clinical knowledge of the treatment guidelines for schizophrenia and major depressive disorders using the “Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE)” project: A nationwide dissemination, education, and evaluation study. Psychiatry Clin Neurosci. 2019;73(10):642–8. https://doi.org/10.1111/pcn.12911.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Numata S, Nakataki M, Hasegawa N, Takaesu Y, Takeshima M, Onitsuka T, Nakamura T, Edagawa R, Edo H, Miura K, et al. Improvements in the degree of understanding the treatment guidelines for schizophrenia and major depressive disorder in a nationwide dissemination and implementation study. Neuropsychopharmacol Rep. 2021;41(2):199–206. https://doi.org/10.1002/npr2.12173.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Yamada H, Motoyama M, Hasegawa N, Miura K, Matsumoto J, Ohi K, Yasui-Furukori N, Numata S, Takeshima M, Sugiyama N, et al. A dissemination and education programme to improve the clinical behaviours of psychiatrists in accordance with treatment guidelines for schizophrenia and major depressive disorders: the Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment (EGUIDE) project. BJPsych Open. 2022;8(3):e83. https://doi.org/10.1192/bjo.2022.44.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Hasegawa N, Yasuda Y, Yasui-Furukori N, Yamada H, Hori H, Ichihashi K, Takaesu Y, Iida H, Muraoka H, Kodaka F, et al. Effect of education regarding treatment guidelines for schizophrenia and depression on the treatment behavior of psychiatrists: A multicenter study. Psychiatry Clin Neurosci. 2023. https://doi.org/10.1111/pcn.13578.

    Article  PubMed  Google Scholar 

  11. Carruthers SP, Brunetti G, Rossell SL. Sleep disturbances and cognitive impairment in schizophrenia spectrum disorders: a systematic review and narrative synthesis. Sleep Med. 2021;84:8–19. https://doi.org/10.1016/j.sleep.2021.05.011.

    Article  PubMed  Google Scholar 

  12. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005;66(10):1254–69. https://doi.org/10.4088/jcp.v66n1008.

    Article  PubMed  Google Scholar 

  13. Furihata R, Uchiyama M, Suzuki M, Konno C, Konno M, Takahashi S, Kaneita Y, Ohida T, Akahoshi T, Hashimoto S, et al. Association of short sleep duration and short time in bed with depression: A Japanese general population survey. Sleep Biol Rhythms. 2015;13(2):136–45. https://doi.org/10.1111/sbr.12096.

    Article  Google Scholar 

  14. Bauer M, Bschor T, Pfennig A, Whybrow PC, Angst J, Versiani M, Moller HJ. Disorders WTFoUD: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry. 2007;8(2):67–104. https://doi.org/10.1080/15622970701227829.

    Article  PubMed  Google Scholar 

  15. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry. 2012;13(5):318–78. https://doi.org/10.3109/15622975.2012.696143.

    Article  PubMed  Google Scholar 

  16. Furihata R, Otsuki R, Hasegawa N, Tsuboi T, Numata S, Yasui-Furukori N, Kashiwagi H, Hori H, Ochi S, Muraoka H, et al. Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study. Sleep Med. 2022;89:23–30. https://doi.org/10.1016/j.sleep.2021.11.005.

    Article  PubMed  Google Scholar 

  17. Okuda S, Qureshi ZP, Yanagida Y, Ito C, Homma Y, Tokita S. Hypnotic prescription trends and patterns for the treatment of insomnia in Japan: analysis of a nationwide Japanese claims database. BMC Psychiatry. 2023;23(1):278. https://doi.org/10.1186/s12888-023-04683-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Takeshima M, Yoshizawa K, Enomoto M, Ogasawara M, Kudo M, Itoh Y, Ayabe N, Takaesu Y, Mishima K. Effects of Japanese policies and novel hypnotics on long-term prescriptions of hypnotics. Psychiatry Clin Neurosci. 2023;77(5):264–72. https://doi.org/10.1111/pcn.13525.

    Article  PubMed  Google Scholar 

  19. Ministry of Health Labour Welfare: Medical fee revision. Retrieved March 19, 2024 form https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000106602.html (in Japanese).

  20. American Psychiatric Association: American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5). Arlington: American Psychiatric Association Publishing; 2013.

    Book  Google Scholar 

  21. Enomoto M, Kitamura S, Tachimori H, Takeshima M, Mishima K. Long-term use of hypnotics: Analysis of trends and risk factors. Gen Hosp Psychiatry. 2020;62:49–55. https://doi.org/10.1016/j.genhosppsych.2019.11.008.

    Article  PubMed  Google Scholar 

  22. Chakos M, Patel JK, Rosenheck R, Glick ID, Hammer MB, Tapp A, Miller A, Miller D. Concomitant psychotropic medication use during treatment of schizophrenia patients: longitudinal results from the CATIE study. Clin Schizophr Relat Psychoses. 2011;5(3):124–34. https://doi.org/10.3371/csrp.5.3.2.

    Article  PubMed  Google Scholar 

  23. Wernicke JF, Sayler ME, Koke SC, Pearson DK, Tollefson GD. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: The absence of an effect related to agitation and suicidal behavior. Depress Anxiety. 1997;6(1):31–9. https://doi.org/10.1002/(sici)1520-6394(1997)6:1%3c31::Aid-da5%3e3.0.Co;2-8.

    Article  CAS  PubMed  Google Scholar 

  24. Morin CM, Jarrin DC, Ivers H, Merette C, LeBlanc M, Savard J. Incidence, Persistence, and Remission Rates of Insomnia Over 5 Years. JAMA Netw Open. 2020;3(11):e2018782. https://doi.org/10.1001/jamanetworkopen.2020.18782.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Zee PC, Bertisch SM, Morin CM, Pelayo R, Watson NF, Winkelman JW, Krystal AD: Long-Term Use of Insomnia Medications: An Appraisal of the Current Clinical and Scientific Evidence. J Clin Med 2023, 12(4).https://doi.org/10.3390/jcm12041629.

  26. Buysse DJ. Insomnia. JAMA. 2013;309(7):706–16. https://doi.org/10.1001/jama.2013.193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. McCall WV, Benca RM, Rosenquist PB, Riley MA, McCloud L, Newman JC, Case D, Rumble M, Krystal AD. Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA. Am J Psychiatry. 2017;174(1):18–25. https://doi.org/10.1176/appi.ajp.2016.16030336.

    Article  PubMed  Google Scholar 

  28. Harvey AG, Soehner AM, Kaplan KA, Hein K, Lee J, Kanady J, Li D, Rabe-Hesketh S, Ketter TA, Neylan TC, et al. Treating insomnia improves mood state, sleep, and functioning in bipolar disorder: a pilot randomized controlled trial. J Consult Clin Psychol. 2015;83(3):564–77. https://doi.org/10.1037/a0038655.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ellis J, Ferini-Strambi L, Garcia-Borreguero D, Heidbreder A, O'Regan D, Parrino L, Selsick H, Penzel T: Chronic Insomnia Disorder across Europe: Expert Opinion on Challenges and Opportunities to Improve Care. Healthcare (Basel) 2023, 11(5).https://doi.org/10.3390/healthcare11050716.

  30. Takeshima M, Enomoto M, Ogasawara M, Kudo M, Itoh Y, Yoshizawa K, Fujiwara D, Takaesu Y, Mishima K. Changes in psychotropic polypharmacy and high-potency prescription following policy change: Findings from a large scale Japanese claims database. Psychiatry Clin Neurosci. 2022;76(9):475–7. https://doi.org/10.1111/pcn.13432.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Laforgue EJ, Istvan M, Schreck B, Mainguy M, Jolliet P, Grall-Bronnec M, Victorri-Vigneau C: Perception of the Regulatory Change for Zolpidem Prescription by French General Practitioners and Its Relation to Prescription Behavior. J Clin Med 2022, 11(8).https://doi.org/10.3390/jcm11082176.

  32. Istvan M, Caillet P, Rousselet M, Guerlais M, Laforgue EJ, Gerardin M, Jolliet P, Feuillet F, Victorri-Vigneau C. Change in the regulatory framework for zolpidem: What is the impact on the landscape of the prescription of sedative medications? The French national ZORRO study. Br J Clin Pharmacol. 2021;87(8):3310–9. https://doi.org/10.1111/bcp.14753.

    Article  CAS  PubMed  Google Scholar 

  33. Buysse DJ. Sleep health: can we define it? Does it matter? Sleep. 2014;37(1):9–17. https://doi.org/10.5665/sleep.3298.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Furihata R, Tateyama Y, Nakagami Y, Akahoshi T, Itani O, Kaneita Y, Buysse DJ. The validity and reliability of the Japanese version of RU-SATED. Sleep Med. 2022;91:109–14. https://doi.org/10.1016/j.sleep.2022.02.014.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the psychiatrists who participated in the EGUIDE project and American Journal Experts (www.aje.com/jp/) for English language editing.

Role of the sponsors

The funders had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

Funding

This work was supported by the Japan Agency for Medical Research and Development (AMED) [numbers JP16dk0307060], [JP19dk0307083], and [JP22dk0307112], JSPS KAKENHI [JP21K17261 and JP23K16273], Health and Labor Sciences Research Grants [H29-Seishin-Ippan-001 and grant number 19GC1201], the Japanese Society of Neuropsychopharmacology, the Japanese Society of Mood Disorders, and the Japanese Society of Clinical Neuropsychopharmacology.

Author information

Author notes

  1. Toshinori Nakamura and Ryuji Furihata are contributed equally to this work.

Authors and Affiliations

  1. Department of Psychiatry, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan

    Toshinori Nakamura

  2. Agency for Student Support and Disability Resources, Kyoto University, Yoshida-Honmachi, Kyoto, 606-8501, Japan

    Ryuji Furihata

  3. Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawahigashi, Kodaira, 187-8553, Japan

    Naomi Hasegawa, Fumitoshi Kodaka, Hiroko Kashiwagi, Hirotaka Yamagata, Kenichiro Miura, Junya Matsumoto, Hisashi Yamada & Ryota Hashimoto

  4. Department of Psychiatry, The Jikei University School of Medicine, 3-18-13 Nishi-Shinbashi, Minato, 105-8471, Japan

    Fumitoshi Kodaka

  5. Department of Psychiatry, Kitasato University School of Medicine, 1-15-1 Kitazato, Sagamihara, 252-0373, Japan

    Hiroyuki Muraoka & Ken Inada

  6. Department of Neuropsychiatry, University of Tokyo Hospital, 7-3-1 Hongo, Bunkyo, 113-8655, Japan

    Kayo Ichihashi

  7. Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Shitsukawa, Toon, 791-0295, Japan

    Shinichiro Ochi

  8. Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, 3-8-15 Kuramoto-cho, Tokushima, 770-8503, Japan

    Shusuke Numata

  9. Department of Neuropsychiatry, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, 181-8611, Japan

    Takashi Tsuboi & Koichiro Watanabe

  10. Department of Psychiatry, Nara Medical University, 840 Shijo-cho, Kashihara, 634-8522, Japan

    Manabu Makinodan

  11. Department of Psychiatry, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Fukuoka, 814-0180, Japan

    Hitoshi Iida & Hikaru Hori

  12. NHO Sakakibara National Hospital, 777 Sakakibara-cho, Tsu, 514-1292, Japan

    Toshiaki Onitsuka

  13. Department of Forensic Psychiatry, National Center Hospital, National Center of Psychiatry and Neurology, 4-1-1 Ogawahigashi, Kodaira, 187-8551, Japan

    Hiroko Kashiwagi

  14. Department of Neuropsychiatry, Akita University Graduate School of Medicine, 1-1-1 Hondo, Akita, 010-8543, Japan

    Masahiro Takeshima

  15. Department of Psychiatry, Hokkaido University Graduate School of Medicine, Kita 15 Nishi 7, Sapporo, 060-8638, Japan

    Naoki Hashimoto

  16. Department of Neuropsychiatry, Kanazawa Medical University, 1-1 Daigaku, Uchinada, 920-0293, Japan

    Tatsuya Nagasawa

  17. Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, 272-8516, Japan

    Masahide Usami

  18. Kokoro Hospital Machida, 2140 Kamioyamadamachi, Machida, Japan

    Hirotaka Yamagata

  19. Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, 903-0215, Japan

    Yoshikazu Takaesu

  20. Department of Psychiatry, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu, 501-1194, Japan

    Kazutaka Ohi

  21. Department of Neuropsychiatry, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Japan

    Hisashi Yamada

  22. Department of Psychiatry, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, 321-0293, Japan

    Norio Yasui-Furukori

Authors
  1. Toshinori Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryuji Furihata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naomi Hasegawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fumitoshi Kodaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hiroyuki Muraoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kayo Ichihashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shinichiro Ochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shusuke Numata
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takashi Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Manabu Makinodan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hitoshi Iida
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Toshiaki Onitsuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Hiroko Kashiwagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Masahiro Takeshima
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Naoki Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Tatsuya Nagasawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Masahide Usami
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Hirotaka Yamagata
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Yoshikazu Takaesu
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Kenichiro Miura
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Junya Matsumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Kazutaka Ohi
    View author publications

    You can also search for this author in PubMed Google Scholar

  23. Hisashi Yamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  24. Hikaru Hori
    View author publications

    You can also search for this author in PubMed Google Scholar

  25. Ken Inada
    View author publications

    You can also search for this author in PubMed Google Scholar

  26. Koichiro Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  27. Ryota Hashimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  28. Norio Yasui-Furukori
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

TN: conceptualization, formal analysis, investigation, methodology, visualization, writing – original draft, and writing – review and editing; RF: conceptualization, formal analysis, investigation, methodology, project administration, validation, visualization, writing – original draft, and writing – review and editing; HN: data curation, funding acquisition, resources, and writing – review and editing; FK, HM, KI, SO, SN, TT: formal analysis, investigation, methodology, validation, and writing – review and editing; MM, HI, TO, HK, MT, NH, TN, MU, HY, YT, KM, JM: investigation, validation, and writing – review and editing; KO, HY: investigation, project administration, validation, and writing – review and editing; HH: formal analysis, investigation, methodology, project administration, validation, and writing – review and editing; KI: formal analysis, investigation, methodology, project administration, supervision, validation, and writing – review and editing; KW: investigation, project administration, supervision, validation, and writing – review and editing; RH: formal analysis, funding acquisition, investigation, methodology, project administration, resources, supervision, validation, and writing – review and editing; NY-F: formal analysis, investigation, methodology, project administration, supervision, validation, and writing – review and editing. All the authors have read and approved the final manuscript.

Corresponding author

Correspondence to Norio Yasui-Furukori.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Ethics Committee of the National Center of Neurology and Psychiatry and each participating institution. Written informed consent was obtained from all participants before participation in the EGUIDE project. Opt-outs were granted, and patient medical record information was collected at each facility participating in the EGUIDE project. The protocol of the EGUIDE project is registered with the University Hospital Medical Information Network Center (UMIN000022645).

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakamura, T., Furihata, R., Hasegawa, N. et al. The effect of education regarding treatment guidelines for schizophrenia and major depressive disorders on psychiatrists' hypnotic medication prescribing behavior: a multicenter study. BMC Psychiatry 24, 399 (2024). https://doi.org/10.1186/s12888-024-05816-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12888-024-05816-x

Keywords

BMC Psychiatry

ISSN: 1471-244X

Contact us